Following on from information provided to NICE by the company in December 2017 the appraisal of Rilimogene galvacirepvec with rilimogene glafolivec for treating chemotherapy-naive metastatic hormone-relapsed prostate cancer [ID1018] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | TA |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in December 2017 the appraisal of Rilimogene galvacirepvec with rilimogene glafolivec for treating chemotherapy-naive metastatic hormone-relapsed prostate cancer [ID1018] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
For further information on our processes and methods, please see our CHTE processes and methods manual